Innovative, Fundable, Early Stage Opportunities
Each company featured in the Emerging Company Showcase was nominated, reviewed and invited to present based upon their innovative science and the quality of their management team. They presented before a panel of ‘Pitch Doctors’, early stage VCs and investors, corporate VCs, strategic partners and other investors and advisors, who asked questions about their science and strategy. View the 2018 showcase presenters here.
2019 Presenting Companies
 |
Acoustic MedSystems, Inc., Savoy, IL: Developing interventional devices and systems for treatment of localized disease. (NINDS) |
 |
Adecto Pharmaceuticals, Boston, MA: Developing an antibody-based therapy targeting cancers that express the ADAM8 protein. (NCI) |
 |
Advanced Chemotherapy Technologies, Raleigh, NC: Developing a novel device for infusing chemotherapies directly into poorly vascularized tumors. (NCI) |
 |
American Life Science Pharmaceuticals, Inc., La Jolla CA: Developing small molecule drugs for treating neurodegenerative diseases, initially focused on traumatic brain injury (TBI) and Alzheimer’s disease (AD). (NINDS) |
 |
AWE Technologies, LLC, Bay Shore, NY – Non-invasive identification & characterization of fluids and materials, as well as manipulating objects by specially adapting wave energies that intersect the spectrum from acoustics to electromagnetics for solving challenging technical problems. |
 |
BioSapien, Inc., New York, NY: Developing novel biodegradable implantable products that delivery active pharmaceutical ingredients (APIs) for oncology & anti-inflammatory therapies or indications. |
 |
C. Light Technologies, Inc. Berkley, CA: Developing a novel device focused on retinal eye-tracking technology to assess neurological health including the prognosis and monitoring of Multiple Sclerosis. (NINDS) |
 |
CardiaTouch Control Systems, New York, NY – Developing haptic (tactile and force) feedback systems that are intended to improve the safety and efficacy of catheter-based cardiovascular procedures. |
 |
ChemioCare, Inc., New York, NY: Improving the profiles of medicines through its proprietary permeation enhanced transdermal technology (PETT) with an initial focus on cancer and supportive care. |
 |
Chronus Pharmaceuticals, Inc., Stony Brook, NY: Developing a Positron Emission Tomography (PET) imaging diagnostic for deep-seated bacterial infections |
 |
CorInnova, Houston, TX: Developing a minimally invasive, soft robotic cardiac device to treat patients who are contra-indicated for the state-of-the-art left ventricular assist devices (LVADs). (NHLBI) |
 |
ENB Therapeutics, New York, NY – Developing combination therapies with immuno-oncology agents to create a new and superior standard of care that blocks key mechanisms of drug resistance, stimulates the immune system to fight cancer, and prevents cancer from spreading. |
 |
Extend Biosciences, Inc., Newton, MA: Developing a novel drug delivery platform technology that improves the pharmacokinetic properties of peptides and proteins. (NCI) |
 |
FocalCool, LLC., Mullica Hill, NJ: Developing a therapeutic device to provide rapid localized cooling to ischemic organs and deliver temperature-sensitive polymers deep inside the body with additional applications in oncology and tissue repair. (NINDS) |
 |
Geneius Biotechnology, Natick, MA – Developing platform technology to re-educate the patient’s own T cells to be responsive to overlooked antigens to deliver a specific and durable immune response less susceptible to tumor immune evasion. |
 |
GLIA, LLC, Boston, MA: Clinical-stage company focused developing Pro-ocular Topical Gel for ocular surface disease. |
 |
GlyTR Therapeutics, Irvine, CA: Developing an entirely new class of immunotherapeutic anti-cancer molecules and cells. (NCI) |
 |
Hillhurst Biopharmaceuticals, Montrose, CA: Developed targeting a protective cellular metabolic pathway to limit inflammatory processes, prevent cell death and prevent complications caused by sickle cell disease. (NHLBI) |
 |
Incysus, New York, NY: Utilizing genetically modified gamma-delta (γδ) T cells to address the challenges that immunotherapies face when targeting cold, low mutation cancers. |
 |
Kaer Biotherapeutics, Escondido, CA : Developing inhaled therapeutics for the treatment of respiratory diseases. (NHLBI) |
 |
KaloCyte, St. Louis, MO: Developing ErythroMer, a dried, bio-inspired artificial red blood cell, to treat life-threatening blood loss when stored red blood cells are unavailable, undesirable or in short supply. (NHLBI) |
 |
Kodikaz Therapeutic Solutions, Inc., pre-clinical gene therapy company which is developing a proprietary non-viral gene transfer methodology, called Zip-Codes. |
 |
LipidSense, Inc., New York, NY: Developing nanosensors for optically detecting lipid accumulation in live animals to accelerate pre-clinical drug-discovery. |
 |
Lucerna, Inc., Brooklyn, NY: Developing a novel, genetically encodable system to fluorescently tag RNAs in cells that overcomes drawbacks of previously described RNA imaging systems. |
 |
Mirimus, Inc., Brooklyn, NY: Develops RNAi and CRISPR/Cas9 genome editing platform technologies to screen for novel drug targets and genetically model therapeutic intervention in live animals and human cell lines. (NCI) |
 |
MicroCures, Bronx, NY: Advancing a drug development platform that designs siRNA-based therapeutics capable of selectively silencing regulatory proteins (MRPs) to enhance healing and treat disease. |
 |
Microvascular Therapeutics, LLC, Tucson, AZ: Developing next generation contrast agents for diagnostic ultrasound. (NHLBI) |
 |
Navega Therapeutics, San Diego, CA – Developing a gene therapy to target pain that is non-addictive, highly specific, and long-lasting. |
 |
Neuroene Therapeutics, Mount Pleasant, SC: Developing novel Vitamin K based therapeutics that target new mechanisms for the treatment of Epilepsy, Parkinsons and Mitochondrial Disease. (NINDS) |
 |
NuvOx Pharma, Tucson, AZ: Clinical stage biotechnology company developing an innovative platform of oxygen therapeutics to treat life-threatening diseases where hypoxia plays a role, including oncology and stroke. (NHLBI) |
 |
OrPro Therapeutics Inc., San Diego, CA: Developing a non-systemic biologic drug platform for treatment of diseases of the lung and other epithelial surfaces characterized by chronic infection, inflammation and obstructive mucus. (NHLBI) |
 |
PainQx, Inc., New York, NY: Developing a next generation approach to objectively measure pain in humans. |
 |
PhaseBio, San Diego, CA: Clinical-stage biopharmaceutical company focused on the development of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. (NHLBI) |
 |
Regenosine, Inc., New York, NY: Developing first-in-class therapies for tissue regeneration. |
 |
Sapience Therapeutics, Inc., Harrison, NY: Developing peptide-based therapeutics to treat previously ‘undruggable’ targets for major unmet medical needs, particularly high mortality cancers including acute myeloid leukemia (AML) and glioblastoma (GBM). |
 |
Sen-Jam Pharmaceutical, Huntington NY: Developing an opioid-free, opioid-sparing pain reliever with GI protection for extended use, reducing the need for opioids, preventing opioid dose escalation, and mitigating opioid withdrawal intensity. |
 |
SIGNABLOK, Inc., Shrewsbury, MA: Developing novel anticancer therapies for targeted treatment of a variety of inflammation-associated diseases. (NCI) |
 |
Spectral MD, Dallaas, TX: Developing DeepView® Wound Imaging System, a systems–based technology that combines real–time digital analysis of optical signatures to sensitize an imager to photon–tissue interactions below the skin’s surface. (NHLBI) |
 |
Summit Biomedical Imaging, LLC, New York, NY: Detecting cancer earlier and more accurately using a small molecule-based, fluorescent diagnostic agent (PARPi-FL) to detect the overexpression of PARP1. |
 |
Sustained Nano Systems, Stony Brook, NY: Developing patented nanotechnology that extends the time release of a wide range of biologically active molecules in a predictable manner, from weeks to months. |
 |
TeraImmune Inc, Rockville, MD: Developing immune cell therapeutics using human regulatory T cells as a therapeutic against autoimmune diseases and immune-related disorders. (NHLBI) |
 |
Theratome Bio, Inc., Indianapolis, IN: Developing therapeutics derived from the secretome of adult stem cells to be first-line therapy for ischemic brain injury, including stroke. (NINDS) |
 |
Thermedical, Waltham, MA: Developing a proprietary thermal ablation therapy that can treat significantly larger tissue volumes with a single device than conventional tools. (NHLBI) |
 |
Third Pole Therapeutics, Arlington, MA: Developing next generation life-saving heart and lung therapies including a simple, convenient, economical, and lightweight device capable of generating nitric oxide from air and electricity (eNO) on-demand and on-site which potentially eliminates the need for large compressed gas cylinders. (NHLBI) |
 |
VentriNova, New York, NY: Developing a gene therapy to deliver cyclin A2 to regenerate and repair cardiac muscle. |
 |
Windgap Medical, Inc., Watertown, MA: Developing a novel drug delivery platform that automates the rehydration and administration of powdered or lyophilized drugs. |
 |
Zata Pharmaceuticals, Inc., Worcester, MA: Platform technology enabling the development of novel therapeutics, blood purification systems, and chemical inactivators for vaccine enhancement. (NHLBI) |
*Select companies are participating with the support the National Institutes of Health – the specific supporting institute, National Cancer Institute (NCI) or National Heart Lung Blood Institute (NHLBI) is noted at the end of the company description.
2019 Participating Strategic Partners and Investors*:
Accelerate NY Seed Fund
Aceras BioMedical, LLC
Aisling Capital LLC
Alexion
Alzheimer’s Drug Discovery Foundation
AstraZeneca
Astute Capital Management LLC
Axon Connected, LLC
Baxter
BioAdvance
Boehringer Ingelheim Pharmaceuticals, Inc.
BorderBioMed LLC
Bruder Consulting International, LLC
Celdara Medical
Continental Advisory Services, LLC
Courage Growth Partners
Cowin Ventures
CTI Life Sciences
Delos Capital
Daiichi Sankyo, Inc.
Dolby Family Ventures
Domain Associates
Elanco Animal Health
Eli Lilly & Company
FC Capital Management
FoxHill Asset Management
Golden Seeds
H.I.G. Capital
Haiyin Capital
Health Investment & Financing Corporation
Hercules Technology Capital
Johnson & Johson Innovation
Landmark Angels and Landmark Family Office
Life Science Angels
Livingston Capital Management
Magid Family Office
Merck
Mid Atlantic Bio Angels (MABA)
Morningside Ventures
Mount One Capital
MPM Capital
NASDAQ
NSIP LLC
OniX Empire Fund
Orange Grove Bio
OrbiMed
Osage University Partners
Pappas Ventures
Park Ave Capital
Pathway Bioventures
Perceptive Advisors
Pfizer
Pfizer Ventures
Regeneron Pharmaceuticals, Inc.
Roche
Solebury Trout
ThinkEquity
Torreya Partners
UK Department for International Trade
Vista Capital Advisors, LLC
*List is for informational purposes only and subject to change without notice